Can-Fite BioPharma Ltd. (CANF) 追踪市盈率为负值 -794.3, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 1.4 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -0.13%, 前瞻盈利收益率 71.43%. PEG 0.06 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 37/100 其中 1/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -95.6 | -8.60 | 170.50 | 3,888.41 | - |
| 2017 | -96.9 | 2.64 | 157.63 | 569.84 | - |
| 2018 | -74.6 | 7.09 | 162.58 | 128.32 | - |
| 2019 | -15.0 | 1.27 | 77.40 | 93.01 | - |
| 2020 | -28.1 | 0.39 | 66.72 | 531.13 | - |
| 2021 | -31.3 | 1.08 | 27.44 | 462.64 | - |
| 2022 | -32.6 | 0.56 | 74.19 | 409.58 | - |
| 2023 | -24.6 | 0.47 | 30.04 | 252.38 | - |
| 2024 | -30.0 | 0.75 | 43.50 | 350.86 | - |
| 2025 | -0.3 | 0.00 | 0.59 | 8.07 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-90.00 | $169.5K | $-6.9M | -4069.3% |
| 2017 | $-57.00 | $844.75K | $-4.97M | -588.2% |
| 2018 | $-51.00 | $3.82M | $-6.57M | -172% |
| 2019 | $-45.00 | $2.03M | $-13.05M | -642.3% |
| 2020 | $-12.69 | $763K | $-14.81M | -1940.5% |
| 2021 | $-8.25 | $853K | $-12.6M | -1476.6% |
| 2022 | $-3.75 | $810K | $-10.53M | -1300.4% |
| 2023 | $-1.80 | $743K | $-7.63M | -1027.5% |
| 2024 | $-1.08 | $674K | $-7.88M | -1169.1% |
| 2025 | $-12.03 | $408.21K | $-9.91M | -2426.7% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.83 | $-0.83 – $-0.83 | $20.6M | $20.6M – $20.6M | 1 |
| 2027 | $0.76 | $0.76 – $0.76 | $168.55M | $168.55M – $168.55M | 1 |
| 2028 | $1.55 | $1.55 – $1.55 | $306.12M | $306.12M – $306.12M | 1 |
| 2029 | $2.27 | $2.27 – $2.27 | $454.53M | $454.53M – $454.53M | 1 |
| 2030 | $2.82 | $2.82 – $2.82 | $614.43M | $614.43M – $614.43M | 1 |
